



## MAYNE PHARMA TO PRESENT AT THE H.C. WAINWRIGHT 25<sup>TH</sup> ANNUAL GLOBAL INVESTMENT CONFERENCE

---

**7 September 2023, Adelaide, Australia:** Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O'Brien, Chief Executive Officer of Mayne Pharma, will present at the H.C. Wainwright 25<sup>th</sup> Annual Global Investment Conference in New York City as follows:

Date: Monday, September 11, 2023

Time: 9:00am US Eastern Time

Webcast: [Click here](#)

To schedule a one-on-one meeting with the Company, please contact [meetings@hcwco.com](mailto:meetings@hcwco.com) at H.C. Wainwright.

The live and archived webcast of the presentation will be accessible from the Company's website [maynepharma.com](http://maynepharma.com) under Investor Relations. The replay of the webcast will be accessible for 90 days.

### For further information contact:

Australia:

Craig Haskins

+61 421 029 843

[ir@maynepharma.com](mailto:ir@maynepharma.com)

USA:

Lisa M. Wilson

T: 917-543-9932

E: [ir@maynepharma.com](mailto:ir@maynepharma.com)

Authorised for release to the ASX by the Chair

### About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40- year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit [maynepharma.com](http://maynepharma.com).